Cris
@crisuarez08
Followers
797
Following
2K
Statuses
1K
GU Oncologist at Vall d’Hebron #kidneyCancer #prostateCancer #bladderCancer @sogug1
Barcelona, Spain
Joined January 2013
RT @DrDanielHeng: Treatment free survival is becoming an important endpoint when looking at different #mRCC treatments. VEGF alone had sh…
0
50
0
RT @urologiaHVH: El Dr. @enrique_trilla , jefe de @urologiaHVH, ha sido nombrado Profesor Titular por la @UABBarcelona de la UD Vall d’Hebr…
0
7
0
Enhorabuena!!!👏🏻👏🏻👏🏻
El Dr. @enrique_trilla , jefe de @urologiaHVH, ha sido nombrado Profesor Titular por la @UABBarcelona de la UD Vall d’Hebron. ¡¡¡Enhorabuena!!!
0
0
1
So honored to be here!! Thanks for such an amazing meeting! @montypal @DrChoueiri @DrRanaMcKay @DrRosenbergMSK
We are so honored to have esteemed international guests like @AndreaNecchi @MichvdHeijden @tompowles1 @AlbigesL @crisuarez08 @DrDanielHeng @kalasri3 join us for #AUC3. And agree w @shilpaonc - learned so much from Andrea’s brilliant talk on variant histo in #NMIBC. Lots to think about! @DrChoueiri @DrRanaMcKay @DrRosenbergMSK
0
2
14
RT @montypal: Great to have you & so many other experts in #kidneycancer & #bladdercancer here, @shilpaonc! It's clear from just the first…
0
9
0
RT @DrChoueiri: 2/NIAGARA trial: Perioperative durvalumab with NAC in operable bladder cancer à EFS and OS benefit. ⏩32% reduction in risk…
0
24
0
Thanks @DrChoueiri !!
It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical clinical need given that ctDNA-based biomarker genotyping can be limited by low ctDNA @NatureComms
0
0
1
RT @DrChoueiri: It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introdu…
0
77
0
RT @ruizjuanc: De repente ha surgido la noticia de la prohibición por parte del #congreso de que la industria farmacéutica soporte la #form…
0
937
0
RT @g_procopio_: Happy to share the results of the prospective multicenter Cassiope trial in mRCC Here the full article:
0
5
0
RT @CARE1Project: CARE's PI's were present in #SOGUG24 Our coordinator and French PI Pr. @AlbigesL in company of Germany's PI @ViktorGruenw…
0
2
0
RT @neerajaiims: Just in @NEJM 👉the primary results of ph3 @SWOG 1011 trial (n=592)👉in pts with muscle-invasive #bladdercancer undergoing r…
0
64
0
RT @shilpaonc: Team 🇯🇵 all-men competing with @TresUramigas all-women team for the @Uromigos 🏆 #UromigosLive24
@tompowles1 @montypal @PGriv…
0
3
0
0
1
2
RT @TresUramigas: 🗣️Nashville #UromigosLive24 🤠👢 Terapia Peri-operatoria en Cáncer de Vejiga músculo invasor ✅ NIAGARA: Durva+Cis/gem vs C…
0
22
0
RT @DrYukselUrun: CheckMate 914 (Part B) failed to show DFS improvement with adjuvant nivolumab vs placebo in localized RCC patients at hig…
0
22
0
RT @tompowles1: The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based…
0
108
0
RT @DrChoueiri: 1/ Results from #LITESPARK-005 are out @NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) @US_FDA appro…
0
143
0